Target family: Bombesin receptors (type: gpcr)
Target: BB<sub>2</sub> receptor

Ligand: [125I][Tyr4]bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.2 pKd
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: [125I]GRP (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [125I][D-Tyr6]bombesin-(6-13)-methyl ester (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.279999732971191 pKd
Reference (Journal): Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes.
Published in: Mol Pharmacol

Ligand: [125I][D-Tyr6]bombesin-(6-13)-methyl ester (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.96 pKd
Reference (Journal): Characterization of bombesin receptors using a novel, potent, radiolabeled antagonist that distinguishes bombesin receptor subtypes.
Published in: Mol Pharmacol

Ligand: Rhodei-litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.51 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: Rhodei-litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.51 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: Rhodei-litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: Rhodei-litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.63 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: ranatensin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.97 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: ranatensin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: ranatensin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.7 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: ranatensin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.7 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.62 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.72 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.52 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.62 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: [Phe13]bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: [Phe13]bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.11 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [Phe13]bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.11 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: PD 176252 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: PD 176252 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: PD 176252 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 9 pKi
Reference (Journal): PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist.
Published in: Bioorg Med Chem Lett

Ligand: PD 168368 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: PD 168368 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: neuromedin C (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: neuromedin C (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: neuromedin C (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.850000381469727 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: neuromedin C (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.31 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: neuromedin B (1-30) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: neuromedin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: neuromedin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: neuromedin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.61 pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: neuromedin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: neuromedin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: neuromedin B (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: MK-5046 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5 pIC50
Reference (Journal): Comparative Pharmacology of Bombesin Receptor Subtype-3, Nonpeptide Agonist MK-5046, a Universal Peptide Agonist, and Peptide Antagonist Bantag-1 for Human Bombesin Receptors.
Published in: Pharmacol Exp Therap

Ligand: litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.22 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: litorin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.78 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: litorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.22 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: [Leu8]-phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.38 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: [Leu8]-phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.38 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [Leu8]-phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: [Leu8]-phyllolitorin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.92 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: [Leu14, ψ 13-14)]bombesin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [Leu14, ψ 13-14)]bombesin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.11 pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: [Leu14]bombesin (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.880000114440918 pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: kuwanon H (Natural product)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.5 pIC50
Reference (Journal): Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry.
Published in: Biochem Biophys Res Commun

Ligand: JMV641 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 9.34000015258789 pIC50
Reference (Journal): Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor.
Published in: J Biol Chem

Ligand: JMV594 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 8.899999618530273 pIC50
Reference (Journal): Molecular basis for selectivity of high affinity peptide antagonists for the gastrin-releasing peptide receptor.
Published in: J Biol Chem

Ligand: JMV594 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 8.899999618530273 pIC50
Reference (Journal): Syntheses and biological activities of potent bombesin receptor antagonists.
Published in: J Pept Res

Ligand: gastrin releasing peptide(14-27) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.74 pKi
Reference (Journal): Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.
Published in: J Biol Chem

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.74 pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: gastrin-releasing peptide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: [D-Tyr6,β-Ala11,N-Me-Ala13,Nle14]bombesin-(6-14) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.5 pKi
Reference (Journal): Identification and stabilization of a highly selective gastrin-releasing peptide receptor agonist.
Published in: J Pept Sci

Ligand: [D-Tpi6, Leu13 ψ(CH2NH)-Leu14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi.
Published in: Int J Pept Protein Res

Ligand: [D-Tpi6, Leu13 ψ(CH2NH)-Leu14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.899999618530273 pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [D-Tpi6, Leu13 ψ(CH2NH)-Leu14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [D-Pro4,D-Trp7,9,10]substance P (4-11) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [D-Pro4,D-Trp7,9,10]substance P (4-11) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [D-Phe6, Stat13, Leu14}Bn(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.
Published in: Eur J Nucl Med Mol Imaging

Ligand: [D-Phe6, Leu13, Cpa14,ψ13-14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [D-Phe6, Leu13, Cpa14,ψ13-14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 9.800000190734863 pKi
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [D-Phe6, Leu13, Cpa14,ψ13-14]bombesin-(6-14) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.38 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [D-Phe6]bombesin(6-13)propylamide (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.22 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [D-Phe6]bombesin(6-13)propylamide (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [D-Phe6]bombesin(6-13)methyl ester (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: [D-Phe6]bombesin(6-13)methyl ester (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [D-Phe6]bombesin(6-13)methyl ester (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5 pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: [D-Phe6,β-Ala11,Phe13,Nle14]bombesin-(6-14) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: [D-Phe6,β-Ala11,Phe13,Nle14]bombesin-(6-14) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Identification and stabilization of a highly selective gastrin-releasing peptide receptor agonist.
Published in: J Pept Sci

Ligand: [D-Phe6,β-Ala11,Phe13,Nle14]bombesin-(6-14) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: [D-Phe12]bombesin (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: D-Nal,Cys,Tyr,D-Trp,Orn,Val,Cys,Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther

Ligand: D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [D-Arg1,D-Trp7,9,Leu11]substance P (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 4.95 pKi
Reference (Journal): Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R).
Published in: Biochemistry

Ligand: [D-Arg1,D-Trp7,9,Leu11]substance P (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.
Published in: Peptides

Ligand: (D-Ala11]bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.
Published in: Peptides

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.39 pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and characterization of cloned human bombesin receptors.
Published in: Mol Pharmacol

Ligand: bombesin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Published in: J Pharmacol Exp Ther